Carbamazepine clearance in hemodialysis and hemoperfusion.
A 47-year-old woman with endstage renal disease and dialysis-induced encephalopathy was being treated with carbamazepine for myoclonus. Her carbamazepine serum concentration appeared to be therapeutic at 5.1 micrograms/ml. She experienced a seizure while on hemodialysis/hemoperfusion that was possibly related to the removal of carbamazepine during dialysis. The elimination of carbamazepine on a dialysis day was compared with elimination on a nondialysis day. The half-life and apparent clearance were the same for each day, indicating that hemodialysis/hemoperfusion had little effect on the overall removal of carbamazepine from the body. The possible reasons for this lack of effect are discussed.
Kandrotas
R J
RJ
Moses H. Cone Memorial Hospital, Greensboro, N.C.
Oles
K S
KS
Gal
P
P
Love
J M
JM
D002220:Carbamazepine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006464:Hemoperfusion / Q000009:adverse effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009207:Myoclonus / Q000188:drug therapy; D006435:Renal Dialysis / Q000009:adverse effects*
D002220:Carbamazepine